Congress should pass legislation similar to the CHIPS Act to support new biomedical production facilities in the United States.

To Do: Pass a CHIPS Act for the Biopharma Industry

As Joe Kennedy writes for The Hill, reducing drug revenues today will lead to a decline in future research and decrease the number of new drug discoveries moving forward.

What Policymakers Should Know About the Link Between Drug Revenues and New Treatments

A considerable share of biopharma research “spills over” and contributes to knowledge discovery and drug development overall, not just in individual firms’ labs.

How the Biopharmaceutical Industry Contributes to Open Scientific Knowledge

Congress should fund a pilot program supporting experimental approaches to technology transfer and commercialization, and the administration should require labs to collect metrics, identify barriers, and hold labs accountable. 

To Do: Support Experimental Approaches to Tech Transfer and Commercialization

Congress should invest in AI and data science training to prepare the next generation of scientists for AI-supported drug development by integrating AI into biomedical research, supporting cross-disciplinary collaboration, and establishing best practices.

To Do: Invest in AI and Data Science Training for Drug Development

Stephen Ezell gave a keynote presentation to the Alpha-1 Foundation 2021 Annual Conference addressing policy priorities to ensure continued American life-sciences innovation leadership.

Ensuring Continued U.S. Biopharmaceutical Competitiveness

The U.S. must go beyond funding R&D to ensure that more of the public investment in knowledge creation translates into innovation and jobs.

Testimony Before U.S. Senate Commerce Committee on Future of Science and Technology Policy

The administration and Congress should reject calls to seize intellectual property rights as a means of controlling the cost of drugs and other innovations developed with federal R&D funding through universities.

To Do: Defend the Bayh-Dole Act

Congress should establish an Advanced Research Projects Agency for Competitiveness (ARPA–C) to fund advanced R&D projects.

To Do: Establish an R&D Partnership for New Drugs

Recommendation

Details

Editors’ Recommendations

Ensuring U.S. Biopharmaceutical Competitiveness

Related

To Do: Pass a CHIPS Act for the Biopharma Industry

What Policymakers Should Know About the Link Between Drug Revenues and New Treatments

How the Biopharmaceutical Industry Contributes to Open Scientific Knowledge